EUVIMEDEUVIMED entdecken
Crossref

Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis

Marco Di Battista iD, Alessandra Della Rossa, Mattia Da Rio, Giammarco De Mattia, Riccardo Morganti, Marta Mosca iD

The Journal of Rheumatology · 2023

DOI: 10.3899/jrheum.221113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Rheumatology, 2023. Verfasst von Marco Di Battista und 5 weiteren Autor:innen. Beteiligte Einrichtung: M. Di Battista, MD, Rheumatology Unit, University of Pisa, Pisa, and Department of Medical Biotechnologies, University of Siena, Siena; dibattista.ma…. Hauptthemen laut MEDLINE: Vascular Diseases, Scleroderma, Systemic, Raynaud Disease, Skin Ulcer. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic sclerosis (SSc) is burdened by Raynaud phenomenon (RP) and digital ulcers (DUs), and sometimes standard vasoactive therapies are ineffective or contraindicated. Selexipag is an oral selective IP prostacyclin receptor agonist approved for the treatment of SSc-related pulmonary arterial hypertension. We aimed to evaluate the clinical and instrumental efficacy of selexipag in SSc digital vasculopathy.

Methods

Patients with SSc with severe digital vasculopathy refractory or with contraindication to all other vasoactive therapies were administered selexipag. RP- and DU-related clinical outcomes were evaluated, and digital perfusion was assessed by laser speckle contrast analysis (LASCA), all at baseline and after 3 months.

Results

Selexipag was administered to 9 patients with SSc (66.6% female, mean age 52.3 [SD 16.6] yrs). One patient had to stop the drug because of adverse effects. After 3 months of selexipag administration, there was a significant reduction in RP daily episodes ( P = 0.01) and RP mean duration ( P = 0.04). The number of DUs decreased from 10 to 4 without reaching statistical significance. A significant improvement in mean perfusion of the fingers ( P = 0.02) was observed with LASCA.

Conclusion

Selexipag showed good potential for the treatment of SSc digital vasculopathy. Our results are certainly preliminary, yet quite encouraging. New trials for the evaluation of selexipag efficacy in SSc digital vasculopathy are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular DiseasesScleroderma, SystemicRaynaud DiseaseSkin UlcerHumansFemaleMiddle AgedMaleFingersLasersAcetamidesPyrazines

Stichwörter der Autor:innen

Raynaud phenomenondigital ulcerslaser speckle contrast analysisselexipagsystemic sclerosisvasculopathy

Substanzen

selexipagAcetamidesPyrazines

Autor:innen und Institutionen

  • M. Di Battista, MD, Rheumatology Unit, University of Pisa, Pisa, and Department of Medical Biotechnologies, University of Siena, Siena; dibattista.marco91@gmail.com.
  • A. Della Rossa, MD, PhD, M. Da Rio, MD, G. De Mattia, MD, M. Mosca, MD, PhD, Rheumatology Unit, University of Pisa, Pisa.
  • R. Morganti, ScD, PhD, Section of Statistics, University of Pisa, Pisa, Italy.

ORCID-Profile: Marco Di Battista, Marta Mosca

Zitieren

APA

Di Battista, M., Della Rossa, A., Da Rio, M., De Mattia, G., Morganti, R., & Mosca, M. (2023). Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.221113

Vancouver

Di Battista M, Della Rossa A, Da Rio M, De Mattia G, Morganti R, Mosca M. Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis. The Journal of Rheumatology. 2023. doi:10.3899/jrheum.221113

BibTeX
@article{DiBattista2023,
  author = {Di Battista, Marco and Della Rossa, Alessandra and Da Rio, Mattia and De Mattia, Giammarco and Morganti, Riccardo and Mosca, Marta},
  title = {Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis},
  journal = {The Journal of Rheumatology},
  year = {2023},
  doi = {10.3899/jrheum.221113}
}
Kostenlos starten →